We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+32.38%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$233M
AUM Growth
+$22.5M
Cap. Flow
-$30.4M
Cap. Flow %
-13.02%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$30.1M
2
AKRO
Akero Therapeutics
AKRO
+$296K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
1
DELISTED
Akero Therapeutics
AKRO
$87.5M 37.5%
3,940,543
-14,315
-0.4% -$296K
DTIL icon
2
Precision BioSciences
DTIL
$215M
$59.2M 25.4%
142,171
– –
TPTX
3
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$44.1M 18.91%
708,233
-632,032
-47% -$30.1M
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$30.6M 13.13%
1,000,000
– –
YARW
5
Yarrow Bioscience
YARW
$98.8M
$6.78M 2.91%
406
– –
VRNA
6
DELISTED
Verona Pharma
VRNA
$5.03M 2.16%
875,000
– –

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q4 2019 Portfolio in Review

As of Q4 2019, venBio Partners held 6 positions worth $233M, up 11% from $211M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $30.4M in Q4 2019, reducing 2 holdings. Its largest reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $30.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q4 2019 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $30.1M.
  • venBio Partners's ten largest holdings make up 100% of its $233M portfolio in Q4 2019.
  • venBio Partners opened 0 new positions and closed 0 in Q4 2019.
  • venBio Partners's portfolio value rose 11% quarter-over-quarter to $233M.

Based on venBio Partners's 13F filing for Q4 2019, filed 13 Feb 2020.